

Amendments to the Specification:

Replace paragraph 27 (page 9, lines 20-31) of the specification with the amended version below.

In contrast to prior art measurements used as biomarkers, measurements in the biomarkers of the present invention preferably include those at much ~~lower~~finer granularity. For example, rather than concentrations of blood cell populations such as CD4<sup>+</sup> T cells, measurements of the present invention can include subspecies of CD4<sup>+</sup> T cells. One reason for considering ~~lower~~finer-grained factors is that modern bioanalytical instruments are capable of making such fine-grained measurements. Clearly, if finer grained measurements are being obtained, then a larger number of total measurements is produced and considered for inclusion in biomarker sets. Additionally, the biomarkers of the present invention can include measurements that do not correspond directly to known biological entities. For example, features of spectral data can include peak locations (i.e., mass-to-charge ratios) and intensities whose responsible molecular species are not yet determined.